Clinical proteomics in obstetrics and neonatology

Expert Review of Proteomics

Volumn 11, Issue 1, 2014, Pages 75-89

  Klein, Julie ^a   Buffin Meyer, Benedicte ^b,c   Mullen, William ^d   Carty, David M ^d   Delles, Christian ^d   Vlahou, Antonia ^e   Mischak, Harald ^a,d   Decramer, Stéphane ^b,c   Bascands, Jean Loup ^b,c   Schanstra, Joost P ^b,c  

^a MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^b INSERM   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

amniotic fluid; biomarkers; blood; mass spectrometry; neonatal diseases; obstetrical care; proteomics; urine

Indexed keywords

BIOLOGICAL MARKER;

AMNION FLUID; AMNIONITIS; CAPILLARY ELECTROPHORESIS; CIRCULATION; DOWN SYNDROME; FETUS DISEASE; HUMAN; INTRAUTERINE GROWTH RETARDATION; KIDNEY DISEASE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NEONATOLOGY; NEWBORN CARE; OBSTETRIC PROCEDURE; OBSTETRICS; OBSTRUCTIVE UROPATHY; PREECLAMPSIA; PREGNANCY DISORDER; PREMATURE LABOR; PROTEOMICS; REVIEW; TWO DIMENSIONAL GEL ELECTROPHORESIS; UMBILICAL CORD BLOOD; URETEROPELVIC JUNCTION OBSTRUCTION; URETHRA VALVE; URINALYSIS; URINE;

ADULT; AMNIOTIC FLUID; BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; DOWN SYNDROME; FEMALE; FETAL BLOOD; FETAL DISEASES; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; NEONATOLOGY; OBSTETRICS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH; PROTEOME; PROTEOMICS;

EID: 84893132247     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2014.872564     Document Type: Review

References (136)

1. Lumley J. Defining the problem: the epidemiology of preterm birth. BJOG 2003; 110(Suppl 20):3-7
2. Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353(19):2001-11
3. Snijders RJ, Noble P, Sebire N, et al. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998;352(9125):343-6
4. Makrigiannakis A, Karamouti M, Drakakis P, et al. Fetomaternal immunotolerance. Am J Reproduct Immunol 2008;60(6):482-96
5. Herr F, Baal N, Zygmunt M. Studies of placental vasculogenesis: a way to understand pregnancy pathology? Z Geburtshilfe Neonatol 2009;213(3):96-100
6. Malassine A, Cronier L. Hormones and human trophoblast differentiation: a review. Endocrine 2002;19(1):3-11
7. Shankar R, Cullinane F, Brennecke SP, Moses EK. Applications of proteomic methodologies to human pregnancy research: a growing gestation approaching delivery? Proteomics 2004;4(7):1909-17
8. Kim YS, Kim MS, Lee SH, et al. Proteomic analysis of recurrent spontaneous abortion: identification of an inadequately expressed set of proteins in human follicular fluid. Proteomics 2006;6(11):3445-54
9. Brewis IA. Proteomics in reproductive research: the potential importance of proteomics to research in reproduction. Hum Reprod 1999;14(12):2927-9
10. Page NM, Kemp CF, Butlin DJ, Lowry PJ. Placental peptides as markers of gestational disease. Reproduction 2002; 123(4):487-95
11. Jauniaux E, Greenwold N, Hempstock J, Burton GJ. Comparison of ultrasonographic and Doppler mapping of the intervillous circulation in normal and abnormal early pregnancies. Fertil Steril 2003;79(1): 100-6
12. Fanos V, Antonucci R, Barberini L, et al. Clinical application of metabolomics in neonatology. J Matern Fetal Neonatal Med 2012;25(Suppl 1):104-9
13. Fanos V, Van Den Anker J, Noto A, et al. Metabolomics in neonatology: fact or fiction? Semin Fetal Neonatal Med 2013; 18(1):3-12
14. Wilson RD; Genetics Committee of the SOGC. Cell-free fetal DNA in the maternal circulation and its future uses in obstetrics. J Obstet Gynaecol Can 2005;27(1):54-62
15. Hurst RE. Does the biomarker search paradigm need re-booting? BMC Urol 2009;9:1
16. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24(8):971-83
17. Mischak H, Schanstra JP. CE-MS in biomarker discovery, validation, and clinical application. Proteomics Clin Appl 2011; l5(1-2):9-23
18. Roscioni SS, De Zeeuw D, Hellemons ME, et al. A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia 2013; 56(2):259-67
19. Metzger J, Negm AA, Plentz RR, et al. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut 2013;62(1):122-30
20. Theodorescu D, Schiffer E, Bauer HW, et al. Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl 2008;2(4):556-70
21. Mischak H, Allmaier G, Apweiler R, et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2010;2(46):46ps42 . Guidelines of clinical proteomics that should lead to improvement of outcomes of clinical proteomics studies and increase the number of valid biomarkers of disease.
22. Mischak H, Ioannidis JP, Argiles A, et al. Implementation of proteomic biomarkers: making it work. Eur J Clin Invest 2012; 42(9):1027-36
23. Koster MP, Pennings JL, Imholz S, et al. Proteomics and Down syndrome screening: a validation study. Prenat Diagn 2010; 30(11):1039-43
24. Mastricci AL, Akolekar R, Kuppusamy R, et al. Are serum protein biomarkers derived from proteomic analysis useful in screening for trisomy 21 at 11-13 weeks? Fetal Diagn Ther 2011;30(1):53-9
25. Myers JE, Tuytten R, Thomas G, et al. Integrated proteomics pipeline yields novel biomarkers for predicting preeclampsia. Hypertension 2013;61(6):1281-8
26. Auer J, Camoin L, Guillonneau F, et al. Serum profile in preeclampsia and intra-uterine growth restriction revealed by iTRAQ technology. J Proteomics 2010; 73(5):1004-17
27. Michel PE, Crettaz D, Morier P, et al. Proteome analysis of human plasma and amniotic fluid by Off-Gel isoelectric focusing followed by nano-LC-MS/MS. Electrophoresis 2006;27(5-6):1169-81
28. Michaels JE, Dasari S, Pereira L, et al. Comprehensive proteomic analysis of the human amniotic fluid proteome: gestational age-dependent changes. J Proteome Res 2007;6(4):1277-85
29. Avent ND, Plummer ZE, Madgett TE, et al. Post-genomics studies and their application to non-invasive prenatal diagnosis. Semin Fetal Neonatal Med 2008; 13(2):91-8
30. Kolch W, Neususs C, Pelzing M, Mischak H. Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev 2005;24(6):959-77
31. Metzger J, Luppa PB, Good DM, Mischak H. Adapting mass spectrometry-based platforms for clinical proteomics applications: the capillary electrophoresis coupled mass spectrometry paradigm. Crit Rev Clin Lab Sci 2009; 46(3):129-52
32. Shen Y, Kim J, Strittmatter EF, et al. Characterization of the human blood plasma proteome. Proteomics 2005;5(15): 4034-45
33. Liu B, Qiu FH, Voss C, et al. Evaluation of three high abundance protein depletion kits for umbilical cord serum proteomics. Proteome Sci 2011;9(1):24
34. Song HJ, Zhang P, Guo XJ, et al. The proteomic analysis of human neonatal umbilical cord serum by mass spectrometry. Acta Pharmacol Sin 2009;30(11):1550-8
35. Decramer S, Gonzalez De Peredo A, Breuil B, et al. Urine in clinical proteomics. Mol Cell Proteomics 2008;7(10): 1850-62
36. Caubet C, Lacroix C, Decramer S, et al. Advances in urinary proteome analysis and biomarker discovery in pediatric renal disease. Pediatr Nephrol 2010;25(1):27-35
37. Thongboonkerd V, Malasit P. Renal and urinary proteomics: current applications and challenges. Proteomics 2005;5(4):1033-42
38. Schaub S, Wilkins J, Weiler T, et al. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 2004;65(1): 323-32
39. Schiffer E, Mischak H, Novak J. High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS. Proteomics 2006;6(20): 5615-27
40. Decramer S, Wittke S, Mischak H, et al. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med 2006;12(4): 398-400
41. Carty DM, Siwy J, Brennand JE, et al. Urinary proteomics for prediction of preeclampsia. Hypertension 2011;57(3): 561-9
42. Klein J, Lacroix C, Caubet C, et al. Fetal urinary peptides to predict postnatal outcome of renal disease in fetuses with posterior urethral valves (PUV). Sci Transl Med 2013;5(198):198ra106 .. Clinical proteomics study showing the identification of fetal urinary biomarkers of a rare renal disease, which allows the prediction of postnatal renal function with high sensitivity and specificity. The fetal urine proteome-based classifier clearly outperformed the currently used clinical tools and upon implementation could contribute to truly informed prenatal counseling.
43. Underwood MA, Gilbert WM, Sherman MP. Amniotic fluid: not just fetal urine anymore. J Perinatol 2005;25(5): 341-8
44. Tsangaris GT, Anagnostopoulos AK, Tounta G, et al. Application of proteomics for the identification of biomarkers in amniotic fluid: are we ready to provide a reliable prediction? EPMA J 2011;2(2): 149-55
45. Heng YJ, Di Quinzio MK, Permezel M, et al. Temporal proteomic analysis of human cervicovaginal fluid with impending term labor. J Proteome Res 2010;9(3): 1344-50
46. Dasari S, Pereira L, Reddy AP, et al. Comprehensive proteomic analysis of human cervical-vaginal fluid. J Proteome Res 2007;6(4):1258-68
47. Tang LJ, De Seta F, Odreman F, et al. Proteomic analysis of human cervical-vaginal fluids. J Proteome Res 2007;6(7):2874-83
48. Swamy GK, Simhan HN, Gammill HS, Heine RP. Clinical utility of fetal fibronectin for predicting preterm birth. J Reprod Med 2005;50(11):851-6
49. Shah SJ, Yu KH, Sangar V, et al. Identification and quantification of preterm birth biomarkers in human cervicovaginal fluid by liquid chromatography/tandem mass spectrometry. J Proteome Res 2009; 8(5):2407-17
50. Albalat A, Mischak H, Mullen W. Clinical application of urinary proteomics/ peptidomics. Expert Rev Proteomics 2011; 8(5):615-29
51. Mischak H, Coon JJ, Novak J, et al. Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev 2009; 28(5):703-24
52. Henzel WJ, Billeci TM, Stults JT, et al. Identifying proteins from two-dimensional gels by molecular mass searching of peptide fragments in protein sequence databases. Proc Natl Acad Sci USA 1993;90(11): 5011-15
53. Henzel WJ, Watanabe C, Stults JT. Protein identification: the origins of peptide mass fingerprinting. J Am Soc Mass Spectrom 2003;14(9):931-42
54. Issaq HJ, Conrads TP, Prieto DA, et al. SELDI-TOF MS for diagnostic proteomics. Anal Chem 2003;75(7):148A-55A
55. Check E. Proteomics and cancer: running before we can walk? Nature 2004; 429(6991):496-7
56. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004; 20(5):777-85
57. Neuhoff N, Kaiser T, Wittke S, et al. Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom 2004;18(2): 149-56
58. Rogers MA, Clarke P, Noble J, et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Canc Res 2003; 63(20):6971-83
59. Albrethsen J, Bogebo R, Olsen J, et al. Preanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serum. Clin Chem Lab Med 2006;44(10): 1243-52
60. Johannesson N, Wetterhall M, Markides KE, Bergquist J. Monomer surface modifications for rapid peptide analysis by capillary electrophoresis and capillary electrochromatography coupled to electrospray ionization-mass spectrometry. Electrophoresis 2004;25(6):809-16
61. Gaspar A, Englmann M, Fekete A, et al. Trends in CE-MS. 2005-2006. Electrophoresis 2008;29(1):66-79
62. Neususs C, Pelzing M, Macht M. A robust approach for the analysis of peptides in the low femtomole range by capillary electrophoresis-tandem mass spectrometry. Electrophoresis 2002;23(18):3149-59
63. Theodorescu D, Wittke S, Ross MM, et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006;7(3):230-40
64. Kaiser T, Kamal H, Rank A, et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104(2):340-9
65. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422(6928):198-207
66. Issaq HJ, Conrads TP, Janini GM, Veenstra TD. Methods for fractionation, separation and profiling of proteins and peptides. Electrophoresis 2002;23(17): 3048-61
67. Delahunty CM, Yates JR III. MudPIT: multidimensional protein identification technology. Biotechniques 2007;43(5):563, 565, 567 passim
68. Gaspari M, Verhoeckx KC, Verheij ER, Van Der Greef J. Integration of two-dimensional LC-MS with multivariate statistics for comparative analysis of proteomic samples. Anal Chem 2006;78(7):2286-96
69. Lehotay DC, Hall P, Lepage J, et al. LCMS/ MS progress in newborn screening. Clin Biochem 2011;44(1):21-31
70. Seger C, Tentschert K, Stoggl W, et al. A rapid HPLC-MS/MS method for the simultaneous quantification of cyclosporine A, tacrolimus, sirolimus and everolimus in human blood samples. Nat Protoc 2009; 4(4):526-34
71. Van Den Ouweland JM, Kema IP. The role of liquid chromatography-tandem mass spectrometry in the clinical laboratory. J Chromatogr B Analyt Technol Biomed Life Sci 2012;883-884:18-32
72. Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods 2012;9(6):555-66
73. Shi T, Su D, Liu T, et al. Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics. Proteomics 2012;12(8):1074-92
74. Huttenhain R, Soste M, Selevsek N, et al. Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci Transl Med 2012;4(142):142ra194
75. Addona TA, Abbatiello SE, Schilling B, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009;27(7): 633-41
76. Agger SA, Marney LC, Hoofnagle AN. Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple- reactionmonitoring mass spectrometry. Clin Chem 2010;56(12):1804-13
77. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011; 13(11):913-20 . Study showing that continous efforts in noninvasive Down's syndrome screening have now led to very low numbers of false positives based upon screening of fetal DNA present in the circulation of the mother.
78. Nicolaides KH, Syngelaki A, Ashoor G, et al. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol 2012;207(5):374-e1-6
79. Fan HC, Blumenfeld YJ, Chitkara U, et al. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci USA 2008; 105(42):16266-71
80. Chiu RW, Chan KC, Gao Y, et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci USA 2008;105(51):20458-63
81. Busch A, Michel S, Hoppe C, et al. Proteome analysis of maternal serum samples for trisomy 21 pregnancies using ProteinChip arrays and bioinformatics. J Histochem Cytochem 2005;53(3):341-3
82. Kolialexi A, Tsangaris GT, Papantoniou N, et al. Application of proteomics for the identification of differentially expressed protein markers for Down syndrome in maternal plasma. Prenatal Diagn 2008; 28(8):691-8
83. Koster MP, Pennings JL, Imholz S, et al. Bead-based multiplexed immunoassays to identify new biomarkers in maternal serum to improve first trimester Down syndrome screening. Prenatal Diagn 2009;29(9): 857-62
84. Nagalla SR, Canick JA, Jacob T, et al. Proteomic analysis of maternal serum in down syndrome: identification of novel protein biomarkers. J Proteome Res 2007; 6(4):1245-57
85. Cho CK, Smith CR, Diamandis EP. Amniotic fluid proteome analysis from Down syndrome pregnancies for biomarker discovery. J Proteome Res 2010;9(7):3574-82
86. Cho CK, Drabovich AP, Karagiannis GS, et al. Quantitative proteomic analysis of amniocytes reveals potentially dysregulated molecular networks in Down syndrome. Clin Proteomics 2013;10(1):2
87. Martinez-Morillo E, Cho CK, Drabovich AP, et al. Development of a multiplex selected reaction monitoring assay for quantification of biochemical markers of down syndrome in amniotic fluid samples. J Proteome Res 2012;11(7):3880-7
88. Cho CK, Drabovich AP, Batruch I, Diamandis EP. Verification of a biomarker discovery approach for detection of Down syndrome in amniotic fluid via multiplex selected reaction monitoring (SRM) assay. J Proteomics 2011;74(10):2052-9
89. WHO. Available form www.who.int/ pmnch/media/news/2012/ 201204-borntoosoon-report.pdf
90. Pereira L, Reddy AP, Jacob T, et al. Identification of novel protein biomarkers of preterm birth in human cervical-vaginal fluid. J Proteome Res 2007;6(4):1269-76
91. Steer PJ. The epidemiology of preterm labour-why have advances not equated to reduced incidence? BJOG 2006; 113(Suppl 3):1-3
92. Buhimschi IA, Christner R, Buhimschi CS. Proteomic biomarker analysis of amniotic fluid for identification of intra-amniotic inflammation. BJOG 2005;112(2):173-81
93. Buhimschi CS, Bhandari V, Hamar BD, et al. Proteomic profiling of the amniotic fluid to detect inflammation, infection, and neonatal sepsis. PLoS Med 2007;4(1): e18
94. Buhimschi CS, Bhandari V, Han YW, et al. Using proteomics in perinatal and neonatal sepsis: hopes and challenges for the future. Curr Opin Infect Dis 2009; 22(3):235-43
95. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008;454(7203): 428-35
96. Mercer BM. Preterm premature rupture of the membranes: current approaches to evaluation and management. Obstet Gynecol Clin North Am 2005;32(3):411-28
97. Simhan HN, Canavan TP. Preterm premature rupture of membranes: diagnosis, evaluation and management strategies. BJOG 2005;112(Suppl 1):32-7
98. Edmondson N, Bocking A, Machin G, et al. The prevalence of chronic deciduitis in cases of preterm labor without clinical chorioamnionitis. Pediatr Dev Pathol 2009; 12(1):16-21
99. Tambor V, Kacerovsky M, Andrys C, et al. Amniotic fluid cathelicidin in PPROM pregnancies: from proteomic discovery to assessing its potential in inflammatory complications diagnosis. PLoS ONE 2012; 7(7):e41164
100. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005;330(7491):565
101. Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010;116(2 Pt 1):402-14
102. Hofmeyr GJ, Duley L, Atallah A. Dietary calcium supplementation for prevention of pre-eclampsia and related problems: a systematic review and commentary. BJOG 2007;114(8):933-43
103. Buhimschi IA, Zhao G, Funai EF, et al. Proteomic profiling of urine identifies specific fragments of SERPINA1 and albumin as biomarkers of preeclampsia. Am J Obstet Gynecol 2008;199(5):551-e1-e16
104. Chen G, Zhang Y, Jin X, et al. Urinary proteomics analysis for renal injury in hypertensive disorders of pregnancy with iTRAQ labeling and LC-MS/MS. Proteomics Clin Appl 2011;5(5-6):300-10
105. Watanabe H, Hamada H, Yamada N, et al. Proteome analysis reveals elevated serum levels of clusterin in patients with preeclampsia. Proteomics 2004;4(2):537-43
106. Shin JK, Han KA, Kang MY, et al. Expression of clusterin in normal and preeclamptic placentas. J Obstet Gynaecol Res 2008;34(4):473-9
107. Blumenstein M, Mccowan LM, Wu S, et al. SCOPE Consortium. Plasma clusterin increased prior to small for gestational age (SGA) associated with preeclampsia and decreased prior to SGA in normotensive pregnancies. Reprod sci 2012;19(6):650-7
108. Kolla V, Jeno P, Moes S, et al. Quantitative proteomic (iTRAQ) analysis of 1st trimester maternal plasma samples in pregnancies at risk for preeclampsia. J Biomed Biotechnol 2012;2012:305964
109. Rasanen J, Girsen A, Lu X, et al. Comprehensive maternal serum proteomic profiles of preclinical and clinical preeclampsia. J Proteome Res 2010;9(8): 4274-81
110. Iniguez G, Argandona F, Medina P, et al. Acid-labile subunit (ALS) gene expression and protein content in human placentas: differences according to birth weight. J Clin Endocrinol Metab 2011;96(1):187-91
111. Park J, Cha DH, Lee SJ, et al. Discovery of the serum biomarker proteins in severe preeclampsia by proteomic analysis. Exp Mol Med 2011;43(7):427-35
112. Chatelain P. Children born with intra-uterine growth retardation (IUGR) or small for gestational age (SGA): long term growth and metabolic consequences. Endocr Regul 2000;34(1):33-6
113. Conde-Agudelo A, Papageorghiou AT, Kennedy SH, Villar J. Novel biomarkers for predicting intrauterine growth restriction: a systematic review and meta-analysis. BJOG 2013;120(6):681-94
114. Wolter M, Rower C, Koy C, et al. A proteome signature for intrauterine growth restriction derived from multifactorial analysis of mass spectrometry-based cord blood serum profiling. Electrophoresis 2012; 33(12):1881-93
115. Cecconi D, Lonardoni F, Favretto D, et al. Changes in amniotic fluid and umbilical cord serum proteomic profiles of foetuses with intrauterine growth retardation. Electrophoresis 2011;32(24):3630-7
116. Chang CP, Mcdill BW, Neilson JR, et al. Calcineurin is required in urinary tract mesenchyme for the development of the pyeloureteral peristaltic machinery. J Clin Invest 2004;113(7):1051-8
117. Klein J, Gonzalez J, Miravete M, et al. Congenital ureteropelvic junction obstruction: human disease and animal models. Int J Exp Pathol 2011;92(3):168-92
118. Decramer S, Bascands JL, Schanstra JP. Non-invasive markers of ureteropelvic junction obstruction. World J Urol 2007; 25(5):457-65
119. Decramer S, Zurbig P, Wittke S, et al. Identification of urinary biomarkers by proteomics in newborns: use in obstructive nephropathy. Contrib Nephrol 2008;160: 127-41
120. Drube J, Zurbig P, Schiffer E, et al. Urinary proteome analysis identifies infants but not older children requiring pyeloplasty. Pediatr Nephrol 2010;25(9):1673-8
121. Bandin F, Siwy J, Breuil B, et al. Urinary proteome analysis at 5-year followup of patients with nonoperated ureteropelvic junction obstruction suggests ongoing kidney remodeling. J Urol 2012;187(3): 1006-11
122. Mesrobian HG. The value of newborn urinary proteome analysis in the evaluation and management of ureteropelvic junction obstruction: a cost-effectiveness study. World J Urol 2009;27(3):379-83
123. Harambat J, Van Stralen KJ, Kim JJ, Tizard EJ. Epidemiology of chronic kidney disease in children. Pediatr Nephrol 2012; 27(3):363-73
124. Morris RK, Quinlan-Jones E, Kilby MD, Khan KS. Systematic review of accuracy of fetal urine analysis to predict poor postnatal renal function in cases of congenital urinary tract obstruction. Prenatal Diagn 2007; 27(10):900-11 . Example of a meta-analysis showing that fetal urine markers used for years in clinical decision-making and prenatal counseling clearly lack sensitivity and specificity, emphasizing the need for new biomarkers.
125. Morris RK, Malin GL, Khan KS, Kilby MD. Antenatal ultrasound to predict postnatal renal function in congenital lower urinary tract obstruction: systematic review of test accuracy. BJOG 2009;116(10): 1290-9
126. Hogan J, Dourthe ME, Blondiaux E, et al. Renal outcome in children with antenatal diagnosis of severe CAKUT. Pediatr Nephrol 2012;27(3):497-502
127. Lopez Pereira P, Martinez Urrutia MJ, Jaureguizar E. Initial and long-term management of posterior urethral valves. World J Urol 2004;22(6):418-24
128. Nasir AA, Ameh EA, Abdur-Rahman LO, et al. Posterior urethral valve. World J pediatr 2011;7(3):205-16
129. Siwy J, Mullen W, Golovko I, et al. Human urinary peptide database for multiple disease biomarker discovery. Proteomics Clin Appl 2011;5(5-6):367-74
130. Von Zur Muhlen C, Schiffer E, Zuerbig P, et al. Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in symptomatic patients. J Proteome Res 2009;8(1):335-45
131. Zimmerli LU, Schiffer E, Zurbig P, et al. Urinary proteomic biomarkers in coronary artery disease. Mol Cell Proteomics 2008; 7(2):290-8
132. Weinstein LS, Xie T, Zhang QH, Chen M. Studies of the regulation and function of the Gs alpha gene GNAS using gene targeting technology. Pharmacol Ther 2007; 115(2):271-91
133. Kelsey G. Epigenetics and imprinted genes: insights from the imprinted GNAS locus. Hormone Res 2009;71(Suppl 2):22-9
134. EURenOmics. Available form www. eurenomics.com
135. Molina F, Dehmer M, Perco P, et al. Systems biology: opening new avenues in clinical research. Nephrol Dial Transplant 2010;25(4):1015-18
136. Dominiczak AF, Herget-Rosenthal S, Delles C, et al. Systems biology to battle vascular disease. Nephrol Dial Transplant 2010;25(4):1019-22